Skip to main content
TipRanks
Go Ultimate75% OFF

Apimeds Pharmaceuticals US, Inc. (APUS) AI Stock Analysis

31 Followers
APUS

Apimeds Pharmaceuticals US, Inc.

(NYSE MKT:APUS)

Select Model
Rating:44.2Neutral
Price Target:$1.50â–¼(-6.25% Downside)
Action:reiterated
Date:11/20/26

The score is pressured primarily by weak financial performance (heavy losses and ongoing cash burn despite only modest early revenue) and a clearly bearish technical trend with negative momentum. Valuation metrics provide limited support due to negative earnings and no dividend. Corporate events are a modest positive, reflecting strategic expansion and strengthened finance leadership, but they are not yet reflected in the core financials.

Positive Factors
Low leverageModest debt relative to equity gives APUS a stronger financial cushion than its earnings profile would suggest. This reduces near-term interest and refinancing pressure and preserves some flexibility to fund commercialization while the company works toward a more sustainable operating model.
Negative Factors
Severe unprofitabilityAPUS’s current revenue base is far too small to absorb its operating cost structure, leaving the company deeply unprofitable despite strong gross margin. Persistent losses weaken retained capital and make future improvement dependent on rapid commercialization, disciplined spending, or additional financing.

Apimeds Pharmaceuticals US, Inc. (APUS) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%APUS-91.79%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.41M
Dividend Yield
―
Average Volume (3M)
3.72M
Price to Earnings (P/E)
-0.1
Beta (1Y)
2.44
Revenue Growth
―
EPS Growth
-377.99%
Country
US
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Apimeds Pharmaceuticals US, Inc. Business Overview & Revenue Model

Company Description

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Insc...

Apimeds Pharmaceuticals US, Inc. Financial Statement Overview

Summary

Overall fundamentals skew weak despite a relatively supportive balance sheet. Revenue only recently emerged (TTM ~$2.9M) and profitability is far from break-even with very large operating and net losses (net margin around -785%). Cash flow is also a key drag with continued negative operating and free cash flow (~-$11.8M TTM), implying ongoing financing needs. Offsetting this, leverage is low (debt-to-equity ~0.07) and equity is sizable (~$140.5M), providing near-term flexibility.

Income Statement

18Very Negative

Balance Sheet

64Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.90M00000
Gross Profit2.82M-5,7060000
EBITDA-25.12M-5.71M-1.27M-739.63K-639.53K-1.02M
Net Income-22.74M-6.00M-1.39M-777.69K-668.67K-1.03M
Balance Sheet
Total Assets153.53M164.18M13.06K422.08K6,171172.17K
Cash, Cash Equivalents and Short-Term Investments17.91K3.64M3,455410.48K6,171171.44K
Total Debt9.61M7.76M596.84K266.89K660.00K400.00K
Total Liabilities13.01M10.84M1.37M390.20K719.78K410.65K
Stockholders Equity140.52M153.35M-1.36M31.87K-713.61K-238.48K
Cash Flow
Free Cash Flow-11.80M-8.98M-733.53K-627.79K-448.17K-823.11K
Operating Cash Flow-11.77M-8.93M-733.53K-627.79K-448.17K-823.11K
Investing Cash Flow-8.09M-10.06M0000
Financing Cash Flow12.89M20.62M326.50K1.03M282.90K400.00K

Apimeds Pharmaceuticals US, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price1.60

Price Trends

50DMA3.39Negative
100DMA4.27Negative
200DMA9.73Negative

Market Momentum

MACD-0.52Positive
RSI27.86Positive
STOCH6.56Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APUS, the sentiment is Negative. The current price of 1.60 is below the 20-day moving average (MA) of 2.55, below the 50-day MA of 3.39, and below the 200-day MA of 9.73, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 27.86 is Positive, neither overbought nor oversold. The STOCH value of 6.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APUS.

Apimeds Pharmaceuticals US, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

APUS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AYTUAYTU55Neutral$28.91M-1.49-69.19%―-8.12%7.24%
CPIXCPIX53Neutral$94.47M1.27202.58%23.73%-39.11%-241.27%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
APUSAPUS44Neutral$3.21M-0.10-17.27%――-377.99%
SNOASNOA43Neutral$4.10M-0.79-36.40%―38.69%58.68%
YCBDYCBD43Neutral$4.25M-1.17-34.25%―10.01%95.01%
BFRIBFRI40Underperform$10.23M-1.32-110.30%―29.85%78.56%

* Healthcare Sector Average

Performance Comparison

0%200%400%APUSSNOAAYTUCPIXYCBDBFRIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
APUS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
APUSApimeds Pharmaceuticals US, Inc.1.60-18.70-92.12%
SNOASonoma Pharmaceuticals, Inc.0.72-2.49-77.51%
AYTUAytu BioScience2.660.6029.13%
CPIXCumberland Pharmaceuticals Inc.5.844.23263.86%
YCBDCbdmd INc0.36-0.16-30.77%
BFRIBiofrontera, Inc.0.53-0.26-33.25%

Apimeds Pharmaceuticals US, Inc. Corporate Events

Business Operations and StrategyProduct-Related Announcements

Apimeds Subsidiary Expands Into On-Chain Insurance Services

Positive
Oct 13, 2026

On Oct. 4, 2026, MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., signed a two-year master maintenance and service agreement with Delaware-based BlockAssure Inc. to build, deploy and operate AssureChain, a dedicated subnet...

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance

Apimeds Pharmaceuticals Appoints Eric Sherb as New CFO

Positive
Oct 1, 2026

Apimeds Pharmaceuticals US, Inc. announced that on September 29, 2026, Interim Chief Financial Officer Erick Frim resigned effective immediately, with the company stating his departure did not stem from any disagreement over operations, policies, or...

Business Operations and Strategy

MindWave expands blockchain services into sports media markets

Positive
Sep 29, 2026

On September 24, 2026, MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., entered a 12‑month strategic technology services agreement with Singapore-based AQUAE Holdings to deploy its MindChain blockchain as the core infrastr...

Delistings and Listing ChangesStock Split

Apimeds Pharmaceuticals Executes Reverse Stock Split and Amendments

Neutral
Sep 23, 2026

Apimeds Pharmaceuticals US, Inc. implemented a one-for-ten reverse stock split of its issued and outstanding common stock, effective July 24, 2026, following stockholder approval obtained on December 1, 2025. In connection with the transaction, the c...

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance

Apimeds Restructures Board and Appoints New Director

Neutral
Sep 11, 2026

On September 10, 2026, Apimeds Pharmaceuticals US, Inc. and its affiliated parties executed a first amendment to their April 24, 2026 confidential settlement and mutual release agreement, restructuring the composition of the company’s board of direct...

Business Operations and Strategy

Apimeds Secures Key Apitox Rights via FreeT Agreement

Positive
Aug 21, 2026

On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with Korea-based FreeT Inc. under which FreeT irrevocably assigned Apimeds its Apitox-related rights originally acquired in 2015. These Assigned Ri...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026